Ragıp ERTAŞ, Kemal ÖZYURT, Çiğdem KARAKÜKÇÜ, Muhammet Reşat AKKUŞ, Emin ÖZLÜ, Atıl AVCI, Mustafa ATASOY

Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria

Background/aim: Spontaneous wheals and/or angioedema lasting longer than six weeks are described as chronic spontaneous urticaria (CSU). Omalizumab is used for the treatment of antihistamine-resistant CSU. The neutrophil-lymphocyte ratio (NLR), platelet- lymphocyte ratio (PLR), mean platelet volume (MPV), and platelet distribution width (PDW) are considered important indicators of inflammation and platelet activation in chronic diseases. We aimed to determine the NLR, PLR, MPV, and PDW levels in patients with CSU compared with healthy controls. We also aimed to investigate the effects of omalizumab therapy on these parameters in CSU patients. Materials and methods: This hospital-based, retrospective study included 143 patients with CSU and 132 healthy controls with a mean age of 40.0 ± 13.17 and 42.0 ± 16.34, respectively. Patients with equal or higher-than-baseline UAS scores at week 12 of omalizumab treatment were considered nonresponders, others were considered responders. We analyzed the neutrophils, lymphocytes, platelet counts, NLR, PLR, MPV, and PDW before, during, and after omalizumab treatment and compared the results with those of healthy controls. Results: CSU patients presented higher baseline MPV (P = 0.035) and lower baseline PDW values (P < 0.001) than healthy controls. There were statistically significant increases in the MPV (P < 0.001), MPV/platelet count (P = 0.005), and PDW (P = 0.003) and there was a statistically significant decrease in the NLR (P = 0.018) during omalizumab treatment. The percent increase of MPV was low in nonresponders (P = 0.009). Nonresponders had lower PDW values than responders (P = 0.040). Conclusion: The increase in the MPV and PDW may be due to platelet activation during omalizumab treatment. The decrease in the NLR may be regarded as an antiinflammatory effect of omalizumab. The effect of omalizumab on platelet and inflammatory markers may be used to discriminate the responders from nonresponders.

Keywords:

Chronic spontaneous urticaria inflammation, platelet, MPV, PDW, NLR, PLR, omalizumab,

PDF

___

Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol 2010; 35: 869-873.
Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, Grattan CE, Kapp A, Merk HF, Rogala B et al. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1427-1443.
Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Giménez-Arnau A, Godse K et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69: 868-887.
Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924-935.
Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on h 1 antihistamines : a randomized , placebo-controlled study. J Invest Dermatol 2015; 135: 67-75.
Ertas R, Ozyurt K, Ozlu E, Ulas Y, Avci A, Atasoy M, Hawro T, Maurer M. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. J Allergy Clin Immunol 2017; 140: 1749-1751.
Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy 2018; 73: 705-712.
Ertaş R, Özyurt K, Yildiz S, Ulaş Y, Turasan A, Avcı A. Adverse reaction to omalizumab in patients with chronic urticaria: flare up or ineffectiveness? Iran J Allergy, Asthma Immunol 2016; 15: 82-86.
Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia 2010; 14: 28-32.
Kasperska-Zając A, Grzanka A, Jarzab J, Misiołek M, Wyszyńska- Chłap M, Kasperski J, Machura E. The association between platelet count and acute phase response in chronic spontaneous urticaria. Biomed Res Int 2014; 2014: 650913.
Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczkiewicz J. the role of hematological indices in patients with acute coronary syndrome. Dis Markers 2017; 2017: 3041565.
Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011; 17: 47-58.
Ihara A, Kawamoto T, Matsumoto K, Shouno S, Morimoto T, Noma Y. relationship between hemostatic factors and the platelet index in patients with ischemic heart disease. Pathophysiol Haemost Thromb 2006; 35: 388-391.
Prajapati JH, Sahoo S, Nikam T, Shah KH, Maheriya B, Parmar M. association of high density lipoprotein with platelet to lymphocyte and neutrophil to lymphocyte ratios in coronary artery disease patients. J Lipids 2014; 2014: 1-8.
Avci A, Avci D, Erden F, Ragip E, Cetinkaya A, Ozyurt K, Atasoy M. Can we use the neutrophil-to-lymphocyte ratio, platelet- to-lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet’s disease? Ther Clin Risk Manag 2017; 13: 881-886.
Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: Associations found in a large population study. J Allergy Clin Immunol 2012;129: 1307-1313.
Chandrashekar L, Rajappa M, Sundar I, Munisamy M, Ananthanarayanan PH, Thappa DM, Toi PCh. Platelet activation in chronic urticaria and its correlation with disease severity. Platelets 2014; 25: 162-165.
Magen E, Mishal J, Zeldin Y, Schlesinger M. Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria. Allergy Asthma Proc 2011; 32: 460-466.
Magen E, Mishal J, Zeldin Y, Feldman V, Kidon M, Schlesinger M, Sthoeger Z. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci 2010; 339: 504-508.
Karabay EA, Çerman AA, Altunay İK. Serum C-reactive protein, neutrophil-lymphocyte ratio and uric acid levels in chronic spontaneous urticaria. Turkiye Klin J Dermatology 2016; 26: 125- 131.
Yalcin AD, Bisgin A, Cetinkaya R, Yildirim M, Gorczynski RM. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma. Clin Lab 2013; 59: 71- 77.
Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, Kitas GD. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-alpha therapy. Rheumatol Int 2010; 30: 1125- 1129.
Chang TW, Chen C, Lin C, Metz M, Church MK. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 135: 337- 342.e2.
Gökmen F, Akbal A, Reşorlu H, Gökmen E, Güven M, Aras AB, Erbağ G, Kömürcü E, Akbal E, Coşar M. neutrophil–lymphocyte ratio connected to treatment options and inflammation markers of ankylosing spondylitis. J Clin Lab Anal 2015; 29: 294-298.
Ledford DK. Omalizumab: overview of pharmacology and efficacy in asthma. Expert Opin Biol Ther 2009; 9: 933-943.
Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy 2009; 39: 788- 797.
Ali A. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. J Asthma Allergy 2012; 5: 1-9.
Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol 2017; 139: 1489-1495.e5.
Cassar K, Bachoo P, Brittenden J. The role of platelets in peripheral vascular disease. Eur J Vasc Endovasc Surg 2003; 25: 6-15.
Bhat TM, Afari ME, Garcia LA. Neutrophil lymphocyte ratio in peripheral vascular disease: a review. Expert Rev Cardiovasc Ther 2016; 14: 871-875.